The study's authors explored data from two different clinical trials, focusing on patients with HFrEF and HFpEF.

“What surprised me is that such small changes in electrolyte values have such dramatic effects,” one researcher said. 

Dapagliflozin can help patients with CKD lower their risk of adverse renal and cardiovascular outcomes, the FDA said in a statement. 

The findings, published in the Journal of the American College of Cardiology, focused on data from the VIVID registry.

Two cardiologists contributed to the analysis, detailing why certain foods and drinks should be avoided.

Researchers presented 30-day data at the SCAI 2021 Scientific Sessions, highlighting the "excellent" outcomes and the importance of constantly working to improve patient care. 

The study’s authors tracked data from 2007 to 2016, focusing on seven low-value services that all received a “D” recommendation from the USPSTF. 

The team's findings were presented at the 101st Annual Meeting of the American Association for Thoracic Surgery and published in the Journal of the American College of Cardiology.

Overall, one-year findings showed that there were no instances of mortality, endocarditis, major stent fractures or surgical intervention among patients who received the Harmony TPV.

The team behind the new guidance also emphasized how important it still is for all adults to get vaccinated.